請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73057
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 謝冠雄(Edward Hsieh) | |
dc.contributor.author | Isin Demir Lin | en |
dc.contributor.author | 林以心 | zh_TW |
dc.date.accessioned | 2021-06-17T07:15:40Z | - |
dc.date.available | 2019-07-17 | |
dc.date.copyright | 2019-07-17 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-15 | |
dc.identifier.citation | 1. Gruber A. (2009), Biotech Funding Trends –Insights from Entrepreneurs and Investors, Wiley-Blackwell
2. Europabio, https://www.europabio.org/biotech-benefits/what-is-biotechnology 3. Hodgson J. (2006), Biotechnology in Europe. Comparative Study for Europa Bio, EuropaBio 4. Ministry of Interior, Taiwan, ROC, Available from: https://www.moi.gov.tw/english/index.aspx 5. Ministry of Economic Affairs, 2019 Introduction to Biotechnology and Pharmaceutical Industries in Taiwan(R.O.C.), Available from: https://www.biopharm.org.tw/images/2019-Introduction-to-Biotechnology-and-Pharmaceutical-Industries-in-Taiwan.pdf 6. Nosella A., Petroni G. and Verbano C. 2005. Characteristics of the Italian biotechnology industry and new business models: The initial results of an empirical study. Technovation, 25(8): 841–55 7. Hsu Y. G., Shyu J. Z. and Tzeng G. H. 2005. Policy tools on the formation of new biotechnology firms in Taiwan. Technovation, 25(3): 281–92. 8. Huang HC., 2011. Technological Innovation Capability Creation potential of open innovation: a cross-level analysis in the biotechnology industry. Technology Analysis & Strategic Management, 23(1) 9. Ministry of Economic Affairs, Taiwan, ROC (2013). Status of Taiwan’s Biotechnology and Pharmaceutical Industries 2011-2012. The Biotechnology and Pharmaceutical Industries promotion office. Available from: http://www.biopharm.org.tw/en/information_content.php?li=2 10. Ministry of Economic Affairs, Taiwan, ROC (2017). Introduction to biotechnology and pharmaceutical industries in Taiwan 2017. Available from: http://www.biopharm.org.tw/download/2017%20Introduction%20to%20Biotechnology%20and%20Pharmaceutical%20Industries%20in%20Taiwan,%20Rep.%20of%20China.pdf 11. Su J., Chang S., Credit Suisse (2017), Taiwan Healthcare Sector Report 12. Rickards, 2016, Taiwan’s Five Pillar Industries and Industrial Upgrading. Taiwan Business Topics. Available from: https://topics.amcham.com.tw/2016/11/taiwans-five-pillar-industries-industrial-upgrading 13. Invest Taiwan (2016), Multinational R&D center in Taiwan. Available from: https://investtaiwan.nat.gov.tw/showSuccessList?lang=eng&search=4 14. GlobalData (2017), Country Focus: Healthcare, Regulatory and Reimbursement Landscape Taiwan 15. Lin (2017), Taiwan initiates plans for 3rd generation national health insurance. Taiwan News. Available from: http://www.taiwannews.com.tw/en/news/3088572 16. Center of Biomedical Industry Innovation Program (2018), Overview of Taiwan’s biomedical industry 17. TFDA (2018), Available from: https://www.fda.gov.tw/ENG/index.aspx 18. World intellectual property organization, Available from: https://www.wipo.int/sme/en/documents/patents_biotech_fulltext.html 19. Clinical Development Success Rates 2006-2015 – BIO, Biomedtracker, Amplion (2016), Available from: https://www.bio.org/press-release/bio-releases-largest-study-ever-clinical-development-success-rates 20. Taipei Exchange, Available from: https://www.tpex.org.tw/web/regular_emerging/creative_emerging/Creative_emerging.php?l=en-us 21. Invest Taiwan, Available from: https://investtaiwan.nat.gov.tw/ 22. OBI Pharma company website, Available from: www.obipharma.com 23. GlobalData database 24. OBI Pharma company presentation, JP Morgan Conference 2019 25. Bloomberg database 26. Yahoofinance, Available from: https://finance.yahoo.com/ 27. Pharmaengine company website, Available from: http://www.pharmaengine.com/ 28. Pharmaengine company presentation, JP Morgan conference 2019 29. Wolff G. (2001), The Biotech Investor’s Bible, John Wiley &Sons 30. American Institute for Cancer Research, worldwide cancer data (2018), Available from: https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data 31. Iqvia report, Available from: https://www.outsourcing-pharma.com/Article/2018/05/29/Global-oncology-market-to-reach-200bn-by-2022-Iqvia-report) 32. Cancer Registry Annual Report (2016), (Health Promotion Administration (2018, December) Available from: https://www.hpa.gov.tw/EngPages/Index.aspx 33. Ministry of Health and Welfare Taiwan Health and Welfare Report 2018, Ministry of Health and Welfare R.O.C 34. Breast Cancer Drugs Market, Available from: https://www.amarketresearchreport.com/breast-cancer-drugs-market-including-top-key-players-like-sun-pharmaceutical-industries-actavis-hospira-bayer-ag-janssen-biotech-and-accord-healthcare/24477/ 35. Pancreatic Cancer: Types of Treatment, Available from: https://www.cancer.net/cancer-types/pancreatic-cancer/types-treatment 36. Mirasol F. (2017), Available from: http://www.biopharminternational.com/adc-development-robust-despite-lackluster-performance?pageID=3 37. Investing.com, Available from: https://www.investing.com/equities/pharmaengine-ratios 38. Drug patent watch, Available from: https://www.drugpatentwatch.com/p/NDA/207793 39. Fulco M., (2016), Available from: https://topics.amcham.com.tw/2016/05/scandal-widens-for-taiwan-pharma-firm-obi/ 40. Central News Agency (2018), Available from: https://www.taiwannews.com.tw/en/news/3606236 41. https://histock.tw/ 42. Hsiu-Wen L., Huang F. (2015), Available from: https://www.taiwannews.com.tw/en/news/2835741 43. TTY Biopharm, Available from: http://eng.tty.com.tw/ec99/rwd1195/news.asp?newsno=50 44. Medtrack database | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73057 | - |
dc.description.abstract | The primary objective of our research was to explore the biotechnology environment in Taiwan and do qualitative valuation analysis of two biotech companies in Taiwan one with approved product on the market and the other one without in order to analyze the decision pattern for investment.
By applying the qualitative valuation analysis tool, adopted from the book The Biotech Investor’s Bible written by George Wolff, and five-star score system we found that the value of the company does not come only with the product on the market, specifically this value comes from the market’s trust of the drug development pipeline and management of the company. Based on our results, we also see that biotech stocks are very dynamic. These stocks follow the global and local market behavior. Also, they have their own dynamics related to the drug development pipeline, corporate news, and regulatory environment. Market expectations and unfulfilled expectations have huge impact on the biotech company stocks. In order to make investment decision, all these factors should be taken into account. Although a reasonable broad research was conducted for these two companies, our research data is limited to generalize this research to whole biotech environment in Taiwan due to the limited number of companies analyzed. This suggests that in order to generalize this justification further analysis with broader number of companies must be conducted. Discoveries of our research clearly reveal the importance of the eight factors discussed in this study to analyze the value of biotech companies for investment. It may also help, in particular with Taiwanese biotech companies, to assess their strategy in relation to improve their credibility and market capitalization with analysis in these eight factors. Finally, the results may also help the investors who would like to improve their biotechnology company portfolios. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:15:40Z (GMT). No. of bitstreams: 1 ntu-108-R05749056-1.pdf: 3657226 bytes, checksum: 4b95af0b18f6e57d03fb170572e75475 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 1.INTRODUCTION 1
1.1 Background 1 1.2 Overview of Taiwan's Biotechnology Industry 2 2. RESEARCH OBJECTIVES & METHODS 3 3. INVESTING IN BIOTECHNOLOGY 4 3.1Biotechnology Environment in Taiwan 4 3.1.1 Governmental Support in Biotechnology Industry 6 3.1.2 Nationwide Biotech Clusters 8 3.2 Biotechnology Policies in Taiwan 9 3.2.1 Research and Development 9 3.2.2 National Healthcare System and Drug Price Cut 10 3.2.3 Partnerships 11 3.2.4 Approved Drugs 12 3.3 R&D Activities and Expenditure 12 3.4 Stock Market and Stock Prices 15 3.5 SWOT Analysis of Biotech Industry in Taiwan 16 4. CASE STUDY COMPARISON 23 4.1 Finding and Selecting of Comparable Biotechnology Company 23 4.2 OBI Pharma 23 4.2.1 Company Overview 23 4.2.2 Company Profile 24 4.2.3 Products 24 4.2.4 Milestones 25 4.2.5 Financial Performance 26 4.2.6 Stock Performance 26 4.3 PharmaEngine 27 4.3.1 Company Overview 27 4.3.2 Company Profile 27 4.3.3 Products 28 4.3.4 Milestones 28 4.3.5 Financial Performance 28 4.3.6 Stock Performance 29 5. RESULTS AND DISCUSSIONS OF COMPARISON STUDY 30 5.1 Corporate Valuation of a Biotechnology Company 30 5.2 The Key Factors for Corporate Valuation 30 5.2.1 Development Pipeline 31 5.2.2 Partnerships and Collaborations 39 5.2.3 Assess the competition 41 5.2.4 Analysis of Tiers 42 5.2.5 Market Consideration 49 5.2.6 Financials 51 5.2.7 Management 57 5.2.8 Business and Regulatory Environment 61 5.3 Discussions 62 5.4 Limitations of the Study 68 6. CONCLUSIONS 69 7. REFERENCES 70 8. APPENDICES 74 | |
dc.language.iso | en | |
dc.title | 以質性價值分析比較新興生技公司:以兩家臺灣新興生技公司為例 | zh_TW |
dc.title | Qualitative Valuation Analysis in Emerging Biotechnology Companies: Comparison Study of Two Biotechnology Companies in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳家麟(Charlie Chen) | |
dc.contributor.oralexamcommittee | 曹承礎(Tim Chou) | |
dc.subject.keyword | biotechnology company,Taiwan,Qualitative valuation,company valuation,stock price,finance, | zh_TW |
dc.relation.page | 81 | |
dc.identifier.doi | 10.6342/NTU201901482 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-15 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 企業管理碩士專班 | zh_TW |
顯示於系所單位: | 管理學院企業管理專班(Global MBA) |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.57 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。